Vivian Fonseca, MD

Vivian Fonseca, MD
 

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
Past President, Science and Medicine
American Diabetes Association

Why do clinicians managing T2D patients need to be aware of the trials, physiologic basis, side effects and other dimensions of fixed ratio, long-acting insulin-GLP-1 RA combination regimens? Video

Why do clinicians managing T2D patients need to be aware of the trials, physiologic basis, side effects and other dimensions of fixed ratio, long-acting insulin-GLP-1 RA combination regimens?

Why do clinicians managing patients with T2D need to be aware of the trials, physiologic basis, side effects and other dimensions of deploying fixed ratio, long-acting insulin-GLP-1 RA combination regimens?
Vivian Fonseca, MD

Vivian Fonseca, MD

Are there differences--pharmacokinetic, safety, weight loss, control of PPG--between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)? Video

Are there differences--pharmacokinetic, safety, weight loss, control of PPG--between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

Are there significant clinical differences—pharmacokinetic, safety, degree of weight loss, control of PPG—between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?
Vivian Fonseca, MD

Vivian Fonseca, MD

From a translational perspective, who are the ideal candidates for fixed ratio combinations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)? Video

From a translational perspective, who are the ideal candidates for fixed ratio combinations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?

From a translational perspective, who are the ideal patient candidates for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?
Vivian Fonseca, MD

Vivian Fonseca, MD

What insights have we gained about drug-based management of the diabetic heart? Video

What insights have we gained about drug-based management of the diabetic heart?

What insights have we gained about drug-based management of the diabetic heart?
Vivian Fonseca, MD

Vivian Fonseca, MD

What is your current perspective on the LEADER Trial and how should we translate its findings to the front lines of diabetes care? Can you describe the trial design? Video

What is your current perspective on the LEADER Trial and how should we translate its findings to the front lines of diabetes care? Can you describe the trial design?

What is your current perspective on the LEADER Trial and how should we translate its findings to the front lines of diabetes care? Can you describe the trial design?
Vivian Fonseca, MD

Vivian Fonseca, MD

How do slow dose titration strategies for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide vs. degludec insulin plus liraglutide, potentially affect the side effects seen? Video

How do slow dose titration strategies for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide vs. degludec insulin plus liraglutide, potentially affect the side effects seen?

How do slow dose titration strategies for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira) potentially affect the side effects seen?
Vivian Fonseca, MD

Vivian Fonseca, MD

From a practical perspective, where are combination insulin-plus-GLP-1 RA regimens likely to fit into the sequencing algorithm for care of patients with T2D? Video

From a practical perspective, where are combination insulin-plus-GLP-1 RA regimens likely to fit into the sequencing algorithm for care of patients with T2D?

From practical perspective, where are combination insulin-plus-GLP-1 RA regimens likely to fit into the sequencing algorithm for care of patients with T2D?
Vivian Fonseca, MD

Vivian Fonseca, MD